Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel life-altering therapeutics for rare and often fatal genetic lipid disorders. The Company’s lead product in Phase III clinical development, lomitapide, is a first-in-class, small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. Aegerion plans to submit an NDA to the FDA, and an MAA to the EMA, in the first quarter of 2012. The Company also plans to initiate a clinical program to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC).